Lucine Lehmann

DEVOTE 3: temporal relationships between severe hypoglycaemia, cardiovascular outcomes and mortality

B. Zinman, S. Heller, T. Pieber, 2017, Diabetologia.

The Efficacy of IDegLira (Insulin Degludec/Liraglutide Combination) in Adults with Type 2 Diabetes Inadequately Controlled with a GLP-1 Receptor Agonist and Oral Therapy: DUAL III Randomized Clinical Trial

B. Bode, Y. Handelsman, R. Simpson, 2016, Diabetes Therapy.

Safety and efficacy of insulin degludec/liraglutide (IDegLira) added to sulphonylurea alone or to sulphonylurea and metformin in insulin‐naïve people with Type 2 diabetes: the DUAL IV trial

H. Rodbard, B. Bode, S. Harris, 2016, Diabetic medicine : a journal of the British Diabetic Association.

Effect of Insulin Glargine Up-titration vs Insulin Degludec/Liraglutide on Glycated Hemoglobin Levels in Patients With Uncontrolled Type 2 Diabetes: The DUAL V Randomized Clinical Trial.

J. Buse, P. Norwood, I. Lingvay, 2016, JAMA.

Rates of hypoglycaemia are lower in patients treated with insulin degludec/liraglutide (IDegLira) than with IDeg or insulin glargine, regardless of the hypoglycaemia definition used

S. Heller, P. Norwood, I. Lingvay, 2017, Diabetes, obesity & metabolism.

Fixed‐ratio combination of insulin degludec and liraglutide (IDegLira) improves cardiovascular risk markers in patients with type 2 diabetes uncontrolled on basal insulin

Lawrence A Leiter, N. Poulter, T. Vilsbøll, 2019, Diabetes, obesity & metabolism.

23. Insulin Degludec/Liraglutide (IDegLira) Is Superior to Insulin Glargine (IG) in A1c Reduction, Risk of Hypoglycemia, and Weight Change: DUAL V Study (166-OR)

J. Buse, P. Norwood, I. Lingvay, 2015, Nederlands Tijdschrift voor Diabetologie.